S W M C Maass1, C Roorda2, A J Berendsen2, P F M Verhaak3, G H de Bock4. 1. University of Groningen, University Medical Center Groningen, Department of General Practice, PO Box 196, 9700 AD Groningen, The Netherlands. Electronic address: S.W.M.C.Maass@umcg.nl. 2. University of Groningen, University Medical Center Groningen, Department of General Practice, PO Box 196, 9700 AD Groningen, The Netherlands. 3. University of Groningen, University Medical Center Groningen, Department of General Practice, PO Box 196, 9700 AD Groningen, The Netherlands; NIVEL, Netherlands Institute of Health Services Research, Utrecht, The Netherlands. 4. University of Groningen, University Medical Center Groningen, Department of Epidemiology, PO Box 30001, 9700 RB Groningen, The Netherlands.
Abstract
OBJECTIVES: It is unclear whether breast cancer survivors have a higher risk of long-term symptoms of depression or anxiety. The aim of this study was to systematically review the evidence about long-term symptoms of depression and anxiety in breast cancer survivors. STUDY DESIGN: Systematic review. MAIN OUTCOME MEASURES: PubMed, Embase, Cochrane and PsycINFO were searched for studies with at least 100 survivors ≥1 year after diagnosis, and which used common questionnaires measuring symptoms of depression or anxiety, by two independent reviewers. The quality was assessed with the NIH 'Quality Assessment Tool' checklist. Prevalence of symptoms of depression and anxiety was compared to time since diagnosis, available control groups and a general female population. RESULTS: Seventeen articles were included in this review with an average quality score of 57% (range 38-86%). The prevalence of symptoms of depression varied from 9.4% to 66.1% and of anxiety from 17.9% to 33.3%. The results on the depression scale suggested an increase in risk of symptoms of depression for breast cancer survivors at one year after diagnosis, which decreases over the ensuing years. Symptoms of anxiety were not more prevalent among the women with early stage breast cancer. CONCLUSIONS: This review suggests a higher prevalence of symptoms of depression among breast cancer survivors than among the general female population, persistent over more than 5 years after diagnosis. Health care providers should be aware of this. There was no indication for an increased prevalence of symptoms of anxiety among breast cancer survivors.
OBJECTIVES: It is unclear whether breast cancer survivors have a higher risk of long-term symptoms of depression or anxiety. The aim of this study was to systematically review the evidence about long-term symptoms of depression and anxiety in breast cancer survivors. STUDY DESIGN: Systematic review. MAIN OUTCOME MEASURES: PubMed, Embase, Cochrane and PsycINFO were searched for studies with at least 100 survivors ≥1 year after diagnosis, and which used common questionnaires measuring symptoms of depression or anxiety, by two independent reviewers. The quality was assessed with the NIH 'Quality Assessment Tool' checklist. Prevalence of symptoms of depression and anxiety was compared to time since diagnosis, available control groups and a general female population. RESULTS: Seventeen articles were included in this review with an average quality score of 57% (range 38-86%). The prevalence of symptoms of depression varied from 9.4% to 66.1% and of anxiety from 17.9% to 33.3%. The results on the depression scale suggested an increase in risk of symptoms of depression for breast cancer survivors at one year after diagnosis, which decreases over the ensuing years. Symptoms of anxiety were not more prevalent among the women with early stage breast cancer. CONCLUSIONS: This review suggests a higher prevalence of symptoms of depression among breast cancer survivors than among the general female population, persistent over more than 5 years after diagnosis. Health care providers should be aware of this. There was no indication for an increased prevalence of symptoms of anxiety among breast cancer survivors.
Authors: Katherine Petrie; Josie Milligan-Saville; Aimée Gayed; Mark Deady; Andrea Phelps; Lisa Dell; David Forbes; Richard A Bryant; Rafael A Calvo; Nicholas Glozier; Samuel B Harvey Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2018-06-05 Impact factor: 4.328
Authors: Jenson Price; Meagan Barrett-Bernstein; Amanda Wurz; Kristina H Karvinen; Jennifer Brunet Journal: Support Care Cancer Date: 2020-05-12 Impact factor: 3.603
Authors: Leah M Pyter; Lorena P Suarez-Kelly; William E Carson; Jasskiran Kaur; Joshua Bellisario; Savannah R Bever Journal: Behav Brain Res Date: 2017-05-04 Impact factor: 3.332
Authors: Laura Q Rogers; Kerry S Courneya; Philip M Anton; Steven Verhulst; Sandra K Vicari; Randall S Robbs; Edward McAuley Journal: Psychooncology Date: 2016-09-06 Impact factor: 3.894
Authors: Cathleen Y Xing; Michelle Doose; Bo Qin; Yong Lin; Tiffany L Carson; Jesse J Plascak; Kitaw Demissie; Chi-Chen Hong; Elisa V Bandera; Adana A M Llanos Journal: Breast Cancer Res Treat Date: 2020-09-10 Impact factor: 4.872